AU6890800A - A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor - Google Patents

A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Info

Publication number
AU6890800A
AU6890800A AU68908/00A AU6890800A AU6890800A AU 6890800 A AU6890800 A AU 6890800A AU 68908/00 A AU68908/00 A AU 68908/00A AU 6890800 A AU6890800 A AU 6890800A AU 6890800 A AU6890800 A AU 6890800A
Authority
AU
Australia
Prior art keywords
pyrrolo
pyrimidin
disodium
dihydro
benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68908/00A
Inventor
Erik Christopher Chelius
Linda Marie Osborne
Sharon Van Den Berghe Snorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU6890800A publication Critical patent/AU6890800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU68908/00A 1999-08-23 2000-08-15 A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor Abandoned AU6890800A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15025499P 1999-08-23 1999-08-23
US60/150254 1999-08-23
US18496400P 2000-02-25 2000-02-25
US60/184964 2000-02-25
PCT/US2000/020777 WO2001014379A2 (en) 1999-08-23 2000-08-15 A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Publications (1)

Publication Number Publication Date
AU6890800A true AU6890800A (en) 2001-03-19

Family

ID=26847471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68908/00A Abandoned AU6890800A (en) 1999-08-23 2000-08-15 A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Country Status (5)

Country Link
EP (1) EP1212325A2 (en)
AU (1) AU6890800A (en)
CO (1) CO5200767A1 (en)
PE (1) PE20010489A1 (en)
WO (1) WO2001014379A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1259513E (en) * 2000-02-25 2004-02-27 Lilly Co Eli NEW CRYSTALLINE FORM OF N-4 - [(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO-2,3-D | PYRIMIDIN-5-YL) ETHYL ACID | - BENZOIL | -L-GLUTAMIC AND PROCESS FOR THEIR OBTENTION
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
KR20090052355A (en) 2006-08-14 2009-05-25 시코르, 인크. Highly pure pemetrexed diacid and processes for the preparation thereof
TWI374886B (en) 2006-08-14 2012-10-21 Sicor Inc Processes for preparing intermediates of pemetrexed
US8629152B2 (en) 2006-08-14 2014-01-14 Sicor, Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
EP2270013A1 (en) * 2006-08-14 2011-01-05 Sicor, Inc. Crystalline form of pemetrexed diacid and process for the preparation thereof
CA2681829A1 (en) 2007-04-03 2008-10-16 Dr. Reddy's Laboratories Ltd. Solid forms of pemetrexed
CN101417998B (en) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 Purification method of pemetrexed salt
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
NZ588957A (en) * 2008-06-06 2013-03-28 Boehringer Ingelheim Int Pharmaceutical combination of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid
WO2010028105A2 (en) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Amorphous pemetrexed disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (en) 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 New crystal form of pemetrexed diacid and method for preparing same
TW201118098A (en) * 2009-08-13 2011-06-01 Reddy S Lab Liimited Dr Processes for preparing pemetrexed
CN102050825B (en) * 2009-11-05 2014-12-17 上海创诺制药有限公司 Method for preparing pemetrexed disodium 2.5 water crystal
WO2011064256A1 (en) 2009-11-24 2011-06-03 Azad Pharmaceutical Ingredients Ag A new crystalline form of pemetrexed disodium
UA105580C2 (en) * 2010-08-02 2014-05-26 Неон Лабораторіс Лтд. Process for preparation of highly pure dialkyl pemetrexed
KR101308767B1 (en) 2011-01-20 2013-12-31 에스티팜 주식회사 Preparation method of Pemetrexed diethyl ester with high purity and the preparation method of pemetrexed disodium salt comprising the thereof
WO2012111027A2 (en) * 2011-02-15 2012-08-23 Hetero Research Foundation Process for pemetrexed disodium
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
KR101767713B1 (en) 2011-03-25 2017-08-11 시노팜 타이완 리미티드 Process for the production of a pemetrexed salt
AU2013333497A1 (en) * 2012-10-17 2015-04-02 Shilpa Medicare Limited Process for preparing pemetrexed di potassium and its hydrates
EP2953616A2 (en) 2013-02-06 2015-12-16 Cipla House Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
EP2997031A1 (en) 2013-05-17 2016-03-23 Instytut Farmaceutyczny Process for the preparation of high purity amorphous pemetrexed disodium and crystalline forms of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid
WO2015008221A1 (en) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
NZ630292A (en) 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
CN103784454B (en) * 2014-01-22 2015-11-18 海南锦瑞制药有限公司 A kind of pharmaceutical composition containing pemetrexed disodium compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001220T2 (en) * 1997-09-26 2001-05-21 Eli Lilly And Company Useful processes and intermediates to make antifolates.

Also Published As

Publication number Publication date
PE20010489A1 (en) 2001-04-27
EP1212325A2 (en) 2002-06-12
WO2001014379A2 (en) 2001-03-01
WO2001014379A3 (en) 2001-09-07
CO5200767A1 (en) 2002-09-27

Similar Documents

Publication Publication Date Title
AU6890800A (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
HK1051856A1 (en) A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor
NO2014030I1 (en) (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile ("Rilpivirine") and any therapeutic form thereof as is covered by the relevant patent such as pharmaceutically acceptable salts of Rilpivirie including the hydrochloride salt of Rilpivirine, and emtricitabine.
CA2031890A1 (en) N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
HUP0204034A3 (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
PT1155015E (en) Process for the production of tert-butyl (e)-(6-¬2-¬4-(4-fluorophenyl)-6-isopropyl-2-¬methyl(methylsulfonyl)amino pyrimidin-5-yl vinyl (4r,6s)-2,2-dimethyl¬1,3 dioxan-4-yl)acetate
CA2191871A1 (en) Piperazine derivatives as 5ht1a antagonists
IL155919A (en) (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia
AU4302896A (en) Derivatives of anthranilic acid useful as fungicides
AU782631C (en) Novel heterocyclic compounds and salts thereof and medicinal use of the same
CA2084490A1 (en) Process for the preparation of pyrrolo[2,3-d]pyrimidines
CA2384037A1 (en) Pyrazolo[4,3-d]pyrimidines
AU5919900A (en) Cyclized amino acid derivatives
AU5404800A (en) Process for the preparation of optically active n-acyl derivatives of methyl n-(2,6-dimethylphenyl)-d-alaninate
AU5428700A (en) Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
WO2001017959A3 (en) Vitronectin receptor antagonists
AU6160498A (en) N-arylsulfonamide- and pyrrolidinecarboxylic acid intermediates, and their use for the preparation of herbicidal 1,3-dioxo-1h-pyrrolo{1,2-c} imidazole derivatives
AU2003224361A1 (en) Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
AU5862398A (en) Process for preparing substituted pyrimidine derivatives
AU2002364804A1 (en) Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses
AU2002230022A1 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
AU2002220571A1 (en) (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6 -tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propio nic acid isopropyl ester, its preparation and its use
IL160162A0 (en) Salts of substituted 1,2,3,4,-tetrahydroisoquinolie-2-carboxylic acid derivatives
AU2002240930A1 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
AU5297296A (en) Piperidine derivatives as diuretic

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase